Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection

Pancreatic Cyst Clinical Trial

— MCN_Tam  

Official title:

A Pilot Study of Chemoprevention With Tamoxifen in Patients With Pre-Invasive Pancreas Mucinous Cystic Neoplasms Who Will Not Undergo Immediate Resection

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06320990
• Other study ID #: 0074-24-CB
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: September 2024
• Est. completion date: May 2027

Study information

• Verified date: June 2024
• Source: University of Nebraska
• Contact: Peggy Heires, BA
• Phone: 402-559-7078
• Email: peggy.heires[@]unmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic mucinous cystic neoplasms (MCN) who will not undergo immediate resection. Up to 15 participants will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks.

Description:

This is an open-label pilot study of tamoxifen as chemoprevention in patients with pancreatic mucinous cystic neoplasms (MCN) who will not undergo immediate resection. Up to 15 participants will be enrolled and take tamoxifen 20mg by mouth daily for up to 24 weeks. The primary endpoints are feasibility of tamoxifen as chemoprevention in participants with pancreatic MCN and objective response rate as assessed by magnetic resonance imaging (MRI). This study is intended to inform the design of a subsequent trial formally powered to detect the benefit of tamoxifen in treating pancreatic MCN.

The clinical features of pancreatic MCN support the influence of sex hormones in the pathogenesis of the disease. Anti-hormonal therapy may therefore constitute an effective approach to treatment of MCN and chemoprevention of pancreatic adenocarcinoma. Preliminary analyses from preclinical studies suggest that tamoxifen inhibits proliferation and apoptosis in MCN epithelial cells and fibroblasts. Investigators hypothesize that in humans, treatment with tamoxifen will lead to cyst regression or stabilization and may spare or delay the need for resection.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: May 2027
• Est. primary completion date: November 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Age = 19 years

• Clinically diagnosed pre-invasive pancreatic mucinous cystic neoplasm (MCN), measurable by cross-sectional imaging

• Surgical resection of the lesion is not planned due to cyst features, patient factors or patient preference

• Females of reproductive potential and males with partners of reproductive potential must agree to employ two methods contraception throughout the study and for up to 3 months following treatment. Non-child-bearing potential is defined as age 45 years or older and no menses for greater than or equal to 12 months or any age with surgical removal of the uterus and/or both ovaries.

• Estimated glomerular filtration rate (eGFR) > 30mL/min/1.73m2

• Willing and able to provide informed consent to and abide by the protocol

Exclusion Criteria:

• Presence of invasive pancreatic adenocarcinoma or high-grade dysplasia

• Presence of a solid component or mural nodule, main pancreatic duct dilation or abrupt caliber change, obstructive jaundice, lymphadenopathy

• Current or prior use of tamoxifen or another estrogen antagonist including, but not limited to, clomifene, raloxifene, fulvestrant, anastrazole; subjects who have previously used an estrogen antagonist are eligible provided the last use was at least 5 years prior to enrollment.

• Current or planned use of hormonal treatments including estrogen, progesterone, androgens, hormone replacement therapy or other types of hormonal contraceptives including implants and depot injections; levonorgestrel-releasing intrauterine device (IUD) is permitted.

• Contraindications to tamoxifen including:

• Pregnancy or nursing

• Known allergy or hypersensitivity to tamoxifen

• Cataracts which affect visual acuity (ie. symptomatic)

• Retinopathy which affects visual acuity (ie. symptomatic)

• Current warfarin use

• History of deep vein thrombosis or pulmonary embolism or other condition which, in the discretion of the treating physician, may significantly increase the individual's risk of venous thromboembolism

• History of stroke

• Known endometrial hyperplasia or personal history of endometrial carcinoma, uterine sarcoma and uterine carcinosarcoma

• History of intestinal disease or major gastric surgery likely to alter absorption of tamoxifen or inability to swallow oral medications

• Uncontrolled illness including but not limited to ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina or uncontrolled cardiac arrhythmias, or other conditions which might jeopardize or preclude the ability of the patient to take tamoxifen or the safety of follow-up visits, scans and procedures

• Elective surgery planned for the study period

• Participation in another clinical study with an investigational product during the last 28 days

• Any subject, in the opinion of the treating physician, who will not be able to tolerate treatment, or the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements

Related Conditions & MeSH terms

• Neoplasms
• Neoplasms, Cystic, Mucinous, and Serous
• Pancreatic Cyst

Intervention

Drug:
• Tamoxifen 20mg
Tamoxifen is a nonsteroidal antiestrogen for oral administration.

Locations

Country	Name	City	State
United States	University of Nebraska Medical Center	Omaha	Nebraska

Sponsors (1)

Lead Sponsor	Collaborator
University of Nebraska

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility, by adherence rate	Adherence rate, defined as the proportion of subjects who take =70% of the prescribed tamoxifen doses with adherence at least 60%, meaning =60% of subjects take =70% of the prescribed tamoxifen doses	6 months (approximately 180 days)
Primary	Feasibility, by retention rate	Retention rate, defined as the proportion of subjects who complete imaging and study procedures at the 6-month visit with retention of at least 50%, meaning at least 50% of subjects complete imaging and study procedures at the 6-month visit	6 months (approximately 180 days)
Secondary	Objective response rate (ORR) of pancreatic MCN	The ORR will be estimated based on the proportion of subjects with complete or partial response on MRI/MRCP; partial response is defined by = 20% decrease in maximal cyst diameter.	12 months (approximately 360 days)